Enzymology
Matrix metalloproteinase inhibitor MMI270 helps chemotherapy fight metastasis
Published in Clinical Trials Week, March 21st, 2005
According to a study from North Ireland, "the orally bioavailable matrix metalloproteinase inhibitor MMI270 reduces tumor growth metastasis in preclinical models. We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA). Entered into the study were 33 patients with advanced colorectal cancer."
"They received FA 200 mg/m2 over 2 hours followed by 5-FU 400 mg/m2 over 15 min and 5-FU 600 mg/m2 over 22 hours on days 1 and 2 of a 14-day cycle. MMI270 commenced with the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2005-03-21)
More Articles from Clinical Trials Week
- Hepatic Encephalopathy
Trial results dispute efficacy of standard management strategies - Non-Hodgkin Lymphoma
Yttrium 90 ibritumomab tiuxetan does not impair subsequent treatment - Pneumococcal Vaccine
Molecular epidemiology of pneumococcal colonization investigated - Vaccine Delivery
Biodegradable microparticles developed for vaccine antigen delivery - Acute Intracerebral Hemorrhage
Journal publishes results of acute intracerebral hemorrhage study - Addiction Medicine
New hope for highly dependent and heavy smokers - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
